Sex and gender differences in gastroesophageal reflux disease

Journal of Neurogastroenterology and Motility

Volumn 22, Issue 4, 2016, Pages 575-588

  Kim, Young Sun ^a   Kim, Nayoung ^b,c   Kim, Gwang Ha ^d  

^a Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Pusan National University School of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Barrett esophagus; Esophagitis; Estrogen; Gender

Indexed keywords

ESTROGEN;

AGING; BARRETT ESOPHAGUS; ENDOSCOPY; ESOPHAGUS MUCOSA; EXPOSURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEALTH CARE NEED; HELP SEEKING BEHAVIOR; HORMONE SUBSTITUTION; HUMAN; IMMUNE RESPONSE; NOCICEPTION; PATHOPHYSIOLOGY; PERMEABILITY BARRIER; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PSYCHOLOGICAL ASPECT; REVIEW; SEX DIFFERENCE; TREATMENT RESPONSE;

EID: 84992206078     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm16138     Document Type: Review

References (125)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
2. Kim N, Lee SW, Cho SI, et al. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther 2008;27:173-185.
3. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology Published Online First: 15 Feb 2016. doi: 10.1053/ j.gastro.2016.02.012.
4. Chen CL, Hsu PI. Current advances in the diagnosis and treatment of nonerosive reflux disease. Gastroenterol Res Pract. 2013;2013:653989.
5. Khan MQ, Alaraj A, Alsohaibani F, Al-Kahtani K, Jbarah S, Al-Ashgar H. Diagnostic utility of impedance-pH monitoring in refractory nonerosive reflux disease. J Neurogastroenterol Motil 2014;20:497-505.
6. de Bortoli N, Martinucci I, Bellini M, et al. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol 2013:19:5787-5797.
7. Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005;162:454-460.
8. Lin M, Gerson LB, Lascar R, Triadafilopoulos G. Features of gastroesophageal reflux disease in women. Am J Gastroenterol 2004;99:1442-1447.
9. Mishima I, Adachi K, Arima N, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol 2005;40:1005-1009.
10. Masaka T, Iijima K, Endo H, et al. Gender differences in oesophageal mucosal injury in a reflux oesophagitis model of rats. Gut 2013;62:6-14.
11. Wizemann TM, Pardue ML. Exploring the biological contributions to human health: does sex matter? Washington, DC: National Academies Press, 2001.
12. Chang L, Toner BB, Fukudo S, et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006;130:1435-1446.
13. Annandale E, Hammarström A. Constructing the 'gender-specific body': a critical discourse analysis of publications in the field of genderspecific medicine. Health (London) 2011;15:571-587.
14. Kilminster S, Downes J, Gough B, Murdoch-Eaton D, Roberts T. Women in medicine-is there a problem? A literature review of the changing gender composition, structures and occupational cultures in medicine. Med Educ 2007;41:39-49.
15. Asanuma K, Iijima K, Shimosegawa T. Gender difference in gastroesophageal reflux diseases. World J Gastroenterol 2016;22:1800-1810.
16. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut 2014;63:1185-1193.
17. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63:871-880.
18. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011;17:14-27.
19. Zavala-Gonzales MA, Azamar-Jacome AA, Meixueiro-Daza A, et al. Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in Mexico. J Neurogastroenterol Motil 2014;20:475-482.
20. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991;151:448-454.
21. Nusrat S, Nusrat S, Bielefeldt K. Reflux and sex: what drives testing, what drives treatment? Eur Gastroenterol Hepatol 2012;24:233-247.
22. Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007;26:453-461.
23. Chiocca JC, Olmos JA, Salis GB, et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther 2005;22:331-342.
24. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol 2005;100:747-753.
25. Chen M, Xiong L, Chen H, Xu A, He L, Hu P. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a populationbased study in south China. Scand J Gastroenterol 2005;40:759-767.
26. El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol 2002;37:899-904.
27. Nilsson M, Lundegårdh G, Carling L, Ye W, Lagergren J. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scand J Gastroenterol 2002;37:626-630.
28. Jaspersen D, Kulig M, Labenz J, et. al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003;17:1515-1520.
29. Menon S, Jayasena H, Nightingale P, Trudgill NJ. Influence of age and sex on endoscopic findings of gastrooesophageal reflux disease: an endoscopy database study. Eur J Gastroenterol Hepatol 2011;23:389-395.
30. Furukawa N, Iwakiri R, Koyama T, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol 1999;34:441-444.
31. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999;94:3468-3472.
32. Ho KY, Chan YH, Kang JY. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country. Am J Gastroenterol 2005;100:1923-1928.
33. Seo GS, Jeon BJ, Chung JS, et al. The prevalence of erosive esophagitis is not significantly increased in a healthy Korean population-could it be explained?: a multi-center prospective study. J Neurogastroenterol Motil 2013;19:70-77.
34. Shim KN, Hong SJ, Sung JK, et al. Clinical spectrum of reflux esophagitis among 25, 536 Koreans who underwent a health check-up: a nationwide multicenter prospective, endoscopy-based study. J Clin Gastroenterol 2009;43:632-638.
35. Lee JH, Kim N, Chung IK, et al. Clinical significance of minimal change lesions of the esophagus in a healthy Korean population: a nationwide multi-center prospective study. J Gastroenterol Hepatol 2008;23(7 Pt 1):1153-1157.
36. Minatsuki C, Yamamichi N, Shimamoto T, et al. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10, 837 subjects in Japan. PLoS One 2013;8:e69891.
37. Moki F, Kusano M, Mizuide M, et al. Association between reflux esophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther 2007;26:1069-1075.
38. Peng S, Cui Y, Xiao YL, et al. Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population. Endoscopy 2009;41:1011-1017.
39. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005;40:275-285.
40. Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-797.
41. Dong Y, Qi B, Feng XY, Jiang CM. Meta-analysis of Barrett's esophagus in China. World J Gastroenterol 2013;19:8770-8779.
42. Chen X, Zhu LR, Hou XH. The characteristics of Barrett's esophagus: an analysis of 4120 cases in China. Dis Esophagus 2009;22:348-353.
43. Chang CY, Lee YC, Lee CT, et al. The application of Prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic Chinese population. Am J Gastroenterol 2009;104:13-20.
44. Choi CY, Suh S, Park JS, et al. [The prevalence of Barrett's esophagus and the comparison of Barrett's esophagus with cardiac intestinal metaplasia in the health screening at a secondary care hospital.] Korean J Gastroenterol 2012;60:219-223. [Korean]
45. Kim JH, Rhee PL, Lee JH, et al. Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol 2007;22:908-912.
46. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-620.
47. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-309.
48. Kubo A, Cook MB, Shaheen NJ, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013;62:1684-1691.
49. Conio M, Blanchi S, Lapertosa G, et al. Long term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-1939.
50. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-1036.
51. Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett's esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol. 2009;43:907-914.
52. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003;18:595-604.
53. Adachi K, Mishiro T, Tanaka S, Hanada K, Kinoshita Y. Gender differences in the time-course changes of reflux esophagitis in Japanese patients. Intern Med 2015;54:869-873.
54. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005;54:1062-1066.
55. van Blankenstein M, Looman CW, Johnston BJ, Caygill CP. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol 2005;100:568-576.
56. Falk GW, Thota PN, Richter JE, Connor JT, Wachsberger DM. Barrett's esophagus in women: demographic features and progression to high-grade dysplasia and cancer. Clin Gastroenterol Hepatol 2005;3:1089-1094.
57. Derakshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009;58:16-23.
58. Nam SY, Choi IJ, Ryu KH, et al. The effect of abdominal visceral fat, circulating inflammatory cytokines, and leptin levels on reflux esophagitis. J Neurogastroenterol Motil 2015;21:247-254.
59. Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Dis Esophagus 2014;27:757-763.
60. Grishina I, Fenton A, Sankaran-Walters S. Gender differences, aging and hormonal status in mucosal injury and repair. Aging Dis 2014;5:160-169.
61. Velders M, Schleipen B, Fritzemeier KH, Zierau O, Diel P. Selective estrogen receptor-β activation stimulates skeletal muscle growth and regeneration. FASEB J 2012;26:1909-1920.
62. Ashcroft GS, Mills SJ, Lei K, et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest 2003;111:1309-1318.
63. Honda J, Iijima K, Asanuma K, et al. Estrogen enhances esophageal barrier function by potentiating occludin expression. Dig Dis Sci 2016;61:1028-1038.
64. Orlando RC, Bryson JC, Powell DW. Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol 1984;246(6 Pt 1):G718-G724.
65. Bhat YM, Bielefeldt K. Capsaicin receptor (TRPV1) and non-erosive reflux disease. Eur J Gastroenterol Hepatol 2006;18:263-270.
66. Chen CL. Visceral hypersensitivity in non-erosive reflux disease: neurogenic overwhelming in esophagus? Dig Dis Sci 2013;58:2131-2132.
67. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008;57:674-683.
68. Yiangou Y, Facer P, Dyer NH, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001;357:1338-1339.
69. Guarino MP, Cheng L, Ma J, et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010;22:746-751, e219.
70. Yoshida N, Kuroda M, Suzuki T, et al. Role of nociceptors/ neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig Dis Sci 2013; 58: 2237-2243.
71. Greaves E, Grieve K, Horne AW, Saunders PT. Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis. J Clin Endocrinol Metab 2014;99:E1738-E1743.
72. Kim JJ, Kim N, Choi YJ, Kim JS, Jung HC. Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extra esophageal reflux symptoms. Medicine (Baltimore). 2016;95:e4387.
73. Ma J, Altomare A, Guarino M, et al. HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012;303:G635-G645.
74. Choi YJ, Kim N, Kim JJ, Lee DH, Park JH, Jung HC. Upregulation of vanilloid receptor-1 in functional dyspepsia with or without Helicobacter pylori infection. Medicine (Baltimore) 2016;95:e3410
75. Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011;193:440-451.
76. Vega KJ, Langford-Legg T, Palacio C, Watts J, Jamal MM. Females without reflux symptoms or gastroesophageal reflux disease have less distal esophageal acid exposure than males without reflux symptoms or gastroesophageal reflux disease. Dis Esophagus 2013;26:246-249.
77. Feng G, Wang J, Zhang L, Liu Y. A study to draw a normative database of laryngopharynx pH profile in Chinese. J Neurogastroenterol Motil 2014;20:347-351.
78. Hartono JL, Mahadeva S, Goh KL. Anxiety and depression in various functional gastrointestinal disorders: do differences exist? J Dig Dis 2012;13:252-257.
79. Vakil N, Niklasson A, Denison H, A Rydén A. Gender differences in symptoms in partial responders to proton pump inhibitors for gastro-oesophageal reflux disease. United European Gastroenterol J 2015;3:443-452.
80. Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. The effect of emotional stress and depression on the prevalence of digestive diseases. J Neurogastroenterol Motil 2015;21:273-282.
81. Fass R, Naliboff BD, Fass SS, et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology 2008;134:696-705.
82. Dean BB, Aguilar D, Johnson LF, et al. Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: frequency, severity and impact on health-related quality of life. Aliment Pharmacol Ther 2008;27:327-337.
83. Dubois RW, Aguilar D, Fass R, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther 2007;25:487-500.
84. Kim JY, Kim N, Seo PJ, et al. Association of sleep dysfunction and emotional status with gastroesophageal reflux disease in Korea. J Neurogastroenterol Motil 2013;19:344-354.
85. Kannampalli P, Sengupta JN. Role of principal ionotropic and metabotropic receptors in visceral pain. J Neurogastroenterol Motil 2015;21:147-158.
86. Nan J, Liu J, Mu J, et al. Brain-based correlations between psychological factors and functional dyspepsia. J Neurogastroenterol Motil 2015;21:103-110.
87. Zhang J, Banerjee B. Role of microRNA in visceral pain. J Neurogastroenterol Motil 2015;21:159-171.
88. Hershcovici T, Fass R Nonerosive reflux disease (NERD)-an update. J Neurogastroenterol Motil 2010;16:8-21.
89. Seedat S, Scott KM, Angermeyer MC, et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 2009;66:785-795.
90. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107:991-1000.
91. Castell DO. Esophageal disorders in the elderly. Gastroenterol Clin North Am 1990;19:235-254.
92. Castell DO. How is esophageal sensitivity impaired with age? In: Giuli R, ed. The esophageal mucosa. Amsterdam: Elsevier Science BV 1994;267-269.
93. Min YW, Lim SW, Lee JH, et al. Prevalence of extraesophageal symptoms in patients with gastroesophageal reflux disease: a multicenter questionnaire-based study in Korea. J Neurogastroenterol Motil 2014;20:87-93.
94. You CR, Oh JH, Seo M, et al. Association between non-erosive reflux disease and high risk of obstructive sleep apnea in Korean population. J Neurogastroenterol Motil 2014:30;20:197-204.
95. Lee HJ, Kim HM, Kim N, et al. Association between halitosis diagnosed by a questionnaire and halimeter and symptoms of gastroesophageal reflux disease. J Neurogastroenterol Motil 2014;20:483-490.
96. Nasseri-Moghaddam S, Mofid A, Ghotbi MH, et al. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther 2008;28:144-153.
97. do Rosário Dias de Oliveira Latorre M, Medeiros da Silva A, Chinzon D, Eisig JN, Dias-Bastos TR. Epidemiology of upper gastrointestinal symptoms in Brazil (EpiGastro): a population-based study according to sex and age group. World J Gastroenterol 2014;20:17388-17398.
98. Nguyen P, Lee SD, Castell DO. Evidence of gender differences in esophageal pain threshold. Am J Gastroenterol 1995;90:901-905.
99. Kapur N, Hunt I, Lunt M, McBeth J, Creed F, Macfarlane G. Primary care consultation predictors in men and women: a cohort study. Br J Gen Pract 2005;55:108-113.
100. Bruley Des Varannes S, Marek L, Humeau B, Lecasble M, Colin R. Gastroesophageal reflux disease in primary care. Prevalence, epidemiology and quality of life of patients. Gastroenterol Clin Biol 2006;30:364-370.
101. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. [Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.] Gastroenterology 1997;112:1448-1456. [French]
102. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14:1589-1594.
103. Ho KY, Kang JY, Seow A. Patterns of consultation and treatment for heartburn: findings from a Singaporean community survey. Aliment Pharmacol Ther 1999;13:1029-1033.
104. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-328.
105. Park CH, Kim HS, Lee SK, et al. Effects of the new prokinetic agent DA-9701 formulated with Corydalis Tuber and Pharbitis Seed in patients with minimal change esophagitis: a bicenter, randomized, double blind, placebo-controlled study. J Neurogastroenterol Motil 2014;20:338-346.
106. Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil 2015;21:309-319.
107. Kim SE, Kim N, Oh S, et al. Predictive factors of response to proton pump inhibitors in Korean patients with gastroesophageal reflux disease. J Neurogastroenterol Motil 2015;21:69-77.
108. Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 2014;20:6-16.
109. Niu XP, Yu BP, Wang YD, et al. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol 2013;19:3124-3129.
110. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010;32:720-737.
111. Ruigomez A, Johansson S, Wernersson B, et al. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol 2012;47:751-761.
112. Heading RC, Monnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011;11:52.
113. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis-a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012;36:635-643.
114. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis-results from the EXPO study. Aliment Pharmacol Ther 2009;29:959-966.
115. Lundell L, Hatlebakk J, Galmiche JP, et al. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial. Curr Med Res Opin 2015;31:65-73.
116. Becker V, Grotz S, Schlag C, et al. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors. World J Gastroenterol 2014;20:4017-4024.
117. Wang AJ, Wang H, Xu L, et al. Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease. Dig Liver Dis 2013;45:296-300.
118. Ashcroft GS, Greenwell-Wild T, Horan MA, Wahl SM, Ferguson MW. Topical estrogen accelerates cutaneous would healing in aged humans associated with an altered inflammatory response. Am J Pathol 1999;155:1137-1146.
119. Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997;3:1209-1215.
120. Menon S, Nightingale P, Trudgill N. Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? United European Gastroenterol J 2014;2:374-382.
121. Green J, Czanner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 2012;130:2387-2396.
122. Lagergren J, Nyrén O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a populationbased cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1998;7:913-915.
123. Nordenstedt H, Zheng Z, Cameron AJ, Ye W, Pedersen NL, Lagergren J. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. Gastroenterology 2008;134:921-928.
124. Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998;115:1374-1380.
125. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290:66-72.